Mark A. Kronenfeld, Director at Pacira Pharmaceuticals, Inc. (PCRX), bought 1,700 shares at $38.72 ($66K) on 2019-03-06, disclosed to the SEC on 2019-03-08.
Open-market purchase of $66k PCRX by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $38.72 | 700 | $27K | 40.9% |
| 2 | $39.14 | 1,000 | $39K | 59.1% |
| Total | $38.97 avg | 1,700 | $66K | 100% |
| Filing → |
| PCRX | BUY | 2017-11-13 | $42K | — | Filing → |
| PCRX | SELL | 2016-06-08 | $42K | — | Filing → |
| PCRX | BUY | 2014-11-04 | $77K | — | Filing → |